Praxis Precision Medicines Inc expected to post a loss of $1.99 a share - Earnings Preview

Praxis Precision Medicines

04/11/2024 15:41

* Praxis Precision Medicines Inc  PRAX.OQ   PRAX.O  is
expected
to show a fall in quarterly revenue when it reports  results on
November 6 for the period ending September 30 2024
    * The Boston Massachusetts-based  company is expected to
report a
36.8% decrease in revenue to $296 thousand from $468 thousand a
year ago, according to the mean estimate from 10 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Praxis Precision
Medicines Inc
is for a loss of $1.99 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Praxis
Precision
Medicines Inc is 150.00​, above​ its last closing price
of $68.33. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -2.26       -2.31      -1.74     Beat    24.8
 Mar. 31 2024  -2.08       -2.08      -2.84     Missed  -36.4
 Dec. 31 2023  -3.23       -3.18      -2.97     Beat    6.8​
 Sep. 30 2023  -5.22       -5.25      -2.70     Beat    48.6
 ​​Jan.        -9.89       -9.83      -7.35     Beat    25.2
 1 0001                                                 
 Mar. 31 2023  -12.07      -11.79     -10.65    Beat    9.6​
 Dec. 31 2022  -12.11      -11.77     -13.05    Missed  -10.8
 Sep. 30 2022  -13.66      -13.29     -14.40    Missed  -8.4
 This summary was machine generated November 4 at 15:41 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)